These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 20622858)

  • 1. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.
    Albizu L; Cottet M; Kralikova M; Stoev S; Seyer R; Brabet I; Roux T; Bazin H; Bourrier E; Lamarque L; Breton C; Rives ML; Newman A; Javitch J; Trinquet E; Manning M; Pin JP; Mouillac B; Durroux T
    Nat Chem Biol; 2010 Aug; 6(8):587-94. PubMed ID: 20622858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.
    Mouillac B; Manning M; Durroux T
    Mini Rev Med Chem; 2008 Sep; 8(10):996-1005. PubMed ID: 18782052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.
    Albizu L; Teppaz G; Seyer R; Bazin H; Ansanay H; Manning M; Mouillac B; Durroux T
    J Med Chem; 2007 Oct; 50(20):4976-85. PubMed ID: 17850055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.
    Terrillon S; Cheng LL; Stoev S; Mouillac B; Barberis C; Manning M; Durroux T
    J Med Chem; 2002 Jun; 45(12):2579-88. PubMed ID: 12036367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time resolved FRET strategy with fluorescent ligands to analyze receptor interactions in native tissues: application to GPCR oligomerization.
    Cottet M; Albizu L; Comps-Agrar L; Trinquet E; Pin JP; Mouillac B; Durroux T
    Methods Mol Biol; 2011; 746():373-87. PubMed ID: 21607869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescent ligands to investigate GPCR binding properties and oligomerization.
    Cottet M; Faklaris O; Falco A; Trinquet E; Pin JP; Mouillac B; Durroux T
    Biochem Soc Trans; 2013 Feb; 41(1):148-53. PubMed ID: 23356275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes.
    Cottet M; Albizu L; Perkovska S; Jean-Alphonse F; Rahmeh R; Orcel H; Méjean C; Granier S; Mendre C; Mouillac B; Durroux T
    Curr Opin Pharmacol; 2010 Feb; 10(1):59-66. PubMed ID: 19896898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.
    Loison S; Cottet M; Orcel H; Adihou H; Rahmeh R; Lamarque L; Trinquet E; Kellenberger E; Hibert M; Durroux T; Mouillac B; Bonnet D
    J Med Chem; 2012 Oct; 55(20):8588-602. PubMed ID: 22984902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A homogeneous G protein-coupled receptor ligand binding assay based on time-resolved fluorescence resonance energy transfer.
    Hu LA; Zhou T; Hamman BD; Liu Q
    Assay Drug Dev Technol; 2008 Aug; 6(4):543-50. PubMed ID: 18699727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective nonpeptidic fluorescent ligands for oxytocin receptor: design, synthesis, and application to time-resolved FRET binding assay.
    Karpenko IA; Margathe JF; Rodriguez T; Pflimlin E; Dupuis E; Hibert M; Durroux T; Bonnet D
    J Med Chem; 2015 Mar; 58(5):2547-52. PubMed ID: 25642985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors.
    Harikumar KG; Morfis MM; Lisenbee CS; Sexton PM; Miller LJ
    Mol Pharmacol; 2006 Jan; 69(1):363-73. PubMed ID: 16244179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutive oligomerization of human D2 dopamine receptors expressed in Spodoptera frugiperda 9 (Sf9) and in HEK293 cells. Analysis using co-immunoprecipitation and time-resolved fluorescence resonance energy transfer.
    Gazi L; López-Giménez JF; Rüdiger MP; Strange PG
    Eur J Biochem; 2003 Oct; 270(19):3928-38. PubMed ID: 14511374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-Resolved FRET-Based Assays to Characterize G Protein-Coupled Receptor Hetero-oligomer Pharmacology.
    Heuninck J; Hounsou C; Dupuis E; Trinquet E; Mouillac B; Pin JP; Bonnet D; Durroux T
    Methods Mol Biol; 2019; 1947():151-168. PubMed ID: 30969415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoselective Acylation of Hydrazinopeptides to Access Fluorescent Probes for Time-Resolved FRET Assays on GPCRs.
    Ramanoudjame SM; Esteoulle L; Riché S; Margathe JF; Durroux T; Karpenko IA; Bonnet D
    Methods Mol Biol; 2019; 1947():137-147. PubMed ID: 30969414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell-surface protein-protein interaction analysis with time-resolved FRET and snap-tag technologies: application to GPCR oligomerization.
    Maurel D; Comps-Agrar L; Brock C; Rives ML; Bourrier E; Ayoub MA; Bazin H; Tinel N; Durroux T; Prézeau L; Trinquet E; Pin JP
    Nat Methods; 2008 Jun; 5(6):561-7. PubMed ID: 18488035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis.
    Terrillon S; Durroux T; Mouillac B; Breit A; Ayoub MA; Taulan M; Jockers R; Barberis C; Bouvier M
    Mol Endocrinol; 2003 Apr; 17(4):677-91. PubMed ID: 12554793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Portraying G protein-coupled receptors with fluorescent ligands.
    Ciruela F; Jacobson KA; Fernández-Dueñas V
    ACS Chem Biol; 2014 Sep; 9(9):1918-28. PubMed ID: 25010291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-resolved FRET binding assay to investigate hetero-oligomer binding properties: proof of concept with dopamine D1/D3 heterodimer.
    Hounsou C; Margathe JF; Oueslati N; Belhocine A; Dupuis E; Thomas C; Mann A; Ilien B; Rognan D; Trinquet E; Hibert M; Pin JP; Bonnet D; Durroux T
    ACS Chem Biol; 2015 Feb; 10(2):466-74. PubMed ID: 25350273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors.
    Lemaire W; O'Brien JA; Burno M; Chaudhary AG; Dean DC; Williams PD; Freidinger RM; Pettibone DJ; Williams DL
    Eur J Pharmacol; 2002 Aug; 450(1):19-28. PubMed ID: 12176104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.